Abstract
Lipoprotein(a) [Lp(a)] is an independent cardiovascular risk factor, found in more than 20% of the world's population. Presently no appropriate pharmacotherapy exists for lowering Lp(a). In Germany, lipid-apheresis (LA) therapy, acutely lowers Lp(a) >60%, is approved for Lp(a)-hyperproteinemia and
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
